Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Clinical trial NCT04180488 · COMPLETED
Trial details
- NCT number
- NCT04180488
- Sponsor
- Sanofi
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-11
- Primary completion
- 2024-08-01
- Enrollment
- 397
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.